Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
NCT00802815 is a phase early 1 interventional trial sponsored by Washington University School of Medicine. As of 21 Nov 2026, it is completed. It studies Etanercept in Inclusion Body Myositis. The registry lists an enrollment of 20 participants at 1 site in 1 country. The registry lists a start date of 30 Apr 2005 and a primary completion date of 31 May 2014.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00802815 |
| Status | Completed |
| Phase | Phase Early 1 |
| Study type | Interventional trial |
| Lead sponsor | Washington University School of Medicine |
| Enrollment | 20 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Inclusion Body Myositis |
| Drugs | Etanercept |
| Start | 30 Apr 2005 |
| Primary completion | 31 May 2014 |
| Study completion | 31 May 2014 |
| Last update posted | 29 May 2014 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Glenn Lopate, MD
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Washington University Department of Neurology
St Louis
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00802815
Each answer restates registry values shown on this page.
What is NCT00802815?
NCT00802815 is a phase early 1 interventional trial sponsored by Washington University School of Medicine. It studies Etanercept in Inclusion Body Myositis.
Who leads NCT00802815?
The registry names Glenn Lopate, MD (principal investigator, Washington University School of Medicine) as the overall official.
Where does NCT00802815 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00802815 study?
The registered drug and biological interventions are Etanercept.
When did NCT00802815 end?
The registry lists a primary completion date of 31 May 2014 and a study completion date of 31 May 2014. The sponsor last updated the record on 29 May 2014.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.